M. Kraus & Co Has $2.42 Million Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• M. Kraus & Co reduced its stake in Becton, Dickinson and Company by 14.1% during Q2, now holding 14,033 shares valued at $2.42 million.
• Institutional investors own 86.97% of Becton, Dickinson's stock, with recent purchases by major firms like GQG Partners and Vanguard Group.
• Becton, Dickinson reported an EPS of $3.68 for the last quarter, exceeding expectations, while revenue increased by 10.4% year-over-year.

M. Kraus & Co cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 14.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,033 shares of the medical instruments supplier's stock after selling 2,302 shares during the period. M. Kraus & Co's holdings in Becton, Dickinson and Company were worth $2,417,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. GQG Partners LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $689,833,000. Vanguard Group Inc. lifted its position in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. Nuveen LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $211,097,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $155,080,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after purchasing an additional 667,957 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock valued at $562,036 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $189.06 on Friday. The firm has a market capitalization of $54.19 billion, a PE ratio of 34.00, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The firm has a fifty day simple moving average of $189.87 and a two-hundred day simple moving average of $186.61. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's payout ratio is 74.82%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Royal Bank Of Canada assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 price target on the stock. Argus boosted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler restated a "neutral" rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.